Alert level: yellow
OPQ: Q-766
Session: 451
Suggested file name: Myocarditis_and_pericarditis_and_the_covid_vaccine
Tabled on: March 11, 2026
Agencies: 
Estimated questions: 11
Estimated responses: 2
Original filename: Q-766 - Myocarditis and pericarditis and the covid vaccine, Response from March 11, 2026.pdf

External links / references:
(none detected)

Extracted PDF text preview:
Q-766
Question
With regard to Health Canada, the Public Health Agency of Canada and reports of myocarditis and pericarditis following
COVID-19 vaccination: (a) what is the standard operating procedure when an Adverse Event Following Immunization report
containing a potential safety signal is received or identi ed; (b) what federal teams, working groups, contract companies and
persons were responsible for requesting, receiving, reviewing and monitoring any Adverse Event Following Immunization
reports with respect to myocarditis and pericarditis following the COVID-19 vaccines from (i) international sources, (ii) the
provinces and territories; (c) after the information in (b) was received, what steps or actions were taken next, by whom, and on
what date; (d) was the Public Health Agency of Canada or Health Canada noti ed of Adverse Event Following Immunization
reports for myocarditis and pericarditis following COVID-19 vaccination, and, if so, for each noti cation, what was the (i)
name of the noti er, (ii) title of the noti er, (iii) form of noti cation, (iv) name of the person who was noti ed, (v) date of the
noti cation; (e) did the Public Health Agency of Canada or Health Canada receive the initial reports of myocarditis and
pericarditis following COVID-19 vaccination from the Israeli Ministry of Health in February 2021, and, if so, (i) who received the
noti cation, (ii) what was the date of the noti cation, (iii) what actions were taken after the noti cation, (iv) who authorized
these actions, including their name, their title and the date of authorization; (f) for each communication between the Public
Health Agency of Canada, Health Canada and all Public Health Agency of Canada or Health Canada COVID-19 task forces or
working groups related to the Israeli Ministry of Health myocarditis and pericarditis safety signal noti cation, what was the (i)
date, (ii) subject, (iii) type and content, of the communication; and (g) what communication related to the myocarditis and
pericarditis safety signal occurred between the Public Health Agency of Canada, Health Canada or the Public Health Agency
of Canada or Health Canada COVID-19 task forces and the COVID-19 vaccine manufacturer, including the (i) date, (ii) subject,
(iii) type and content, of the communication?
Response
This response was tabled in the House of Commons on March 11, 2026, as Sessional Paper 8555-451-766.
Order/Address of the House of Commons
Tabled on
March 11, 2026
Sessional Paper
8555-451-766
House of Commons
Health Canada
Reply by: the Minister of Health
Name of Signatory: Maggie Chi
Reply
Health Canada
(a) what is the standard operating procedure when an Adverse Event
Following Immunization report containing a potential safety signal is
received or identi ed?
Adverse events following immunization reports are collected in two databases. The Canada Vigilance Program, managed
by Health Canada, receives adverse events following immunization reports from manufacturers who are required to submit
domestic and international reports in accordance with the Food and Drugs Act , Canadian hospitals, healthcare
professionals, and consumers. Adverse events following immunization reports submitted by provincial and territorial public
health authorities are captured in the Canadian Adverse Events Following Immunization Surveillance System, which is
managed by the Public Health Agency of Canada.
Reports from these databases are monitored continuously by Health Canada and the Public Health Agency of Canada. The
most recent COVID-19 vaccine safety reports can be found here. It is important to note that these reports do not
necessarily imply a causal relationship between the adverse event and the vaccine. However, they are an important source
of information supporting ongoing safety monitoring.
(b) what federal teams, working groups, contract companies and
persons were responsible for requesting, receiving, reviewing and
monitoring any Adverse Event Following Immunization reports with
respect to myocarditis and pericarditis following the COVID-19
Question number
Q-766
Asked by
Ted Falk (Provencher)
Date asked
January 22, 2026
Presented by
Kevin Lamoureux
Parliamentary Secretary to the
Leader of the Government in
the House of Commons

vaccines from (i) international sources, (ii) the provinces and
territories; (c) after the information in (b) was received, what steps or
actions were taken next, by whom, and on what date; (d) was the
Public Health Agency of Canada or Health Canada noti ed of Adverse
Event Following Immunization reports for myocarditis and pericarditis
following COVID-19 vaccination, and, if so, for each noti cation, what
was the (i) name of the noti er, (ii) title of the noti er, (iii) form of
noti cation, (iv) name of the person who was noti ed, (v) date of the
noti cation?
Health Canada monitors safety information from multiple sources, including the scientific literature, manufacturers and
international regulators. Furthermore, Health Canada assesses COVID-19 vaccine adverse events following immunization
reports submitted to the Department’s Canada Vigilance Program. Health Canada medical experts evaluate reported
events to determine whether they are causally linked to the vaccine. A causality assessment involves careful consideration
of many factors including, but not limited to, the biology of the reported event and how it could be related to the vaccine,
patient medical history and concurrent conditions as well as the timing between the administration of the vaccine and the
onset of the event. If new safety issues are confirmed, Health Canada will take appropriate action.
As of January 26, 2026 the Canada Vigilance Program of Health Canada has received 2,040 domestic and 29,619 foreign
adverse events following immunization reports for myocarditis and pericarditis following COVID ‑ 19 vaccination.
The table below provides a summary of the domestic reports received with the following information for each adverse
events following immunization report:
*personal information (including their name) is protected as per the Privacy Act.
The table below provides a summary of the foreign reports received with the following information for each adverse events
following immunization report:
Adverse Reaction
Report Number
(i) name of
the notifier *
(ii) title of
the notifier
(iii) form of
notification
(iv) name of the
person who was
notified
(v) date of the
notification
Adverse Reaction
Report Number
(i) name of
the notifier*
(ii) title of
the notifier
(iii) form of
notification
(iv) name of the
person who was
notified
(v) date of the
notification

*personal information (including their name) is protected as per the Privacy Act.
(e) did the Public Health Agency of Canada or Health Canada receive
the initial reports of myocarditis and pericarditis following COVID-19
vaccination from the Israeli Ministry of Health in February 2021, and, if
so, (i) who received the noti cation, (ii) what was the date of the
noti cation, (iii) what actions were taken after the noti cation, (iv) who
authorized these actions, including their name, their title and the date
of authorization; (f) for each communication between the Public Health
Agency of Canada, Health Canada and all Public Health Agency of
Canada or Health Canada COVID-19 task forces or working groups
related to the Israeli Ministry of Health myocarditis and pericarditis
safety signal noti cation, what was the (i) date, (ii) subject, (iii) type
and content, of the communication; (g) what communication related to
the myocarditis and pericarditis safety signal occurred between the
Public Health Agency of Canada, Health Canada or the Public Health
Agency of Canada or Health Canada COVID-19 task forces and the
COVID-19 vaccine manufacturer, including the (i) date, (ii) subject, (iii)
type and content, of the communication?
In February 2021, Health Canada received notification from the Israeli Ministry of Health that they were investigating a
safety signal of